Skip to main content
main-content

Breast cancer

Breast cancer

18-05-2022 | Oncology | Highlight | Article

ABC–DO shows poor breast cancer treatment compliance in sub-Saharan Africa

A high proportion of women with nonmetastatic breast cancer in sub-Saharan Africa do not initiate or complete treatment, show data from the African Breast Cancer–Disparities in Outcomes prospective cohort.

17-05-2022 | Oncology | News | Article

Infertility linked to male breast cancer risk

Men who are infertile may have an increased risk for developing breast cancer, suggests a national case–control study published in Breast Cancer Research.

16-05-2022 | Oncology | News | Article

WSG-ADAPT data may help guide chemotherapy use for HR-positive, HER2-negative EBC

The use of adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative early breast cancer and up to three positive lymph nodes could be guided by the 21-gene recurrence score and response to preoperative endocrine therapy, research suggests.

12-05-2022 | Oncology | News | Article

Meta-analysis highlights increased COVID-19 mortality risk in cancer patients

Results of a large systematic review and meta-analysis show that people with cancer have a significantly greater risk for death from SARS-CoV-2 infection than their cancer-free peers, particularly if they have lung or hematologic cancer.

11-05-2022 | Oncology | News | Article

Trastuzumab deruxtecan approved in USA for HER2-positive advanced breast cancer

Read more about this regular approval here

09-05-2022 | Oncology | News | Article

Trastuzumab deruxtecan CNS activity demonstrated in HER2-positive breast cancer

The antibody–drug conjugate trastuzumab deruxtecan induces a high intracranial response rate among women with HER2-positive breast cancer and active brain metastases, TUXEDO-1 study findings indicate.

06-05-2022 | Oncology | News | Article

Ribociclib plus fulvestrant OS gain for advanced breast cancer continues after 5 years

Exploratory analyses from the MONALEESA-3 trial after more than 5 years of follow-up show that first-line use of ribociclib alongside fulvestrant continues to offers a significant overall survival benefit versus fulvestrant alone in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

06-05-2022 | Oncology | News | Article

DAISY: HER2 levels ‘key determinant’ of trastuzumab deruxtecan activity

The response to trastuzumab deruxtecan in patients with metastatic breast cancer differs significantly by tumoral levels of HER2 expression, indicate results from the DAISY trial.

05-05-2022 | Oncology | News | Article

Patritumab deruxtecan active in HR+, HER2– early breast cancer

One dose of patritumab deruxtecan induces a clinically meaningful response in women with hormone receptor-positive, HER2-negative early breast cancer, show data from the SOLTI TOT-HER3 trial.

05-05-2022 | Oncology | News | Article

Datopotamab deruxtecan–durvalumab combo shows promise for advanced TNBC

Early results from the BEGONIA trial point to the potential of first-line treatment with datopotamab deruxtecan plus durvalumab in people with advanced triple-negative breast cancer.

26-04-2022 | Oncology | News | Article

ASCO issues updated guideline on biomarker assays for early breast cancer adjuvant therapy

Click through for more information on this update

08-04-2022 | Oncology | News | Article

monarchE PRO data bolster adjuvant abemaciclib use in early breast cancer

The patient-reported outcomes from the monarchE trial add support for the addition of abemaciclib to endocrine therapy in the treatment of high-risk, early breast cancer, say the researchers.

28-03-2022 | Oncology | News | Article

Cell-free microRNA shows promise as breast cancer prognostic marker

Total plasma cell-free microRNA levels may be suitable as a prognostic biomarker for breast cancer, research shows.

21-03-2022 | Oncology | News | Article

OlympiA update: Olaparib OS benefit for germline BRCA1/2 early breast cancer patients

Updated results from the OlympiA trial indicate that use of adjuvant olaparib significantly improves overall survival compared with placebo for patients with HER2-negative, early-stage breast cancer who have germline BRCA1/2 mutations.

17-03-2022 | Oncology | News | Article

NeoTRIP: No pCR benefit from atezolizumab–chemotherapy in TNBC patients

The addition of atezolizumab to neoadjuvant carboplatin and nab-paclitaxel does not significantly increase the rate of pathologic complete response among women undergoing surgery for treatment-naïve triple-negative breast cancer, research suggests.

16-03-2022 | Oncology | News | Article

Endocrine therapy de-escalation a possibility for ER-low positive breast cancer

Women with estrogen receptor-low positive breast cancer may be considered for 2 to 3 years of endocrine therapy rather than the standard 5 years without a negative impact on disease-free survival, Chinese researchers report.

15-03-2022 | Oncology | News | Article

Breast cancer patients at increased risk for COVID-19

Individuals with breast cancer may have a greater risk for acquiring SARS-CoV-2 infection than those with other cancer types, suggests Italian research.

07-03-2022 | Oncology | News | Article

Trastuzumab biosimilar equivalent to referent drug in neoadjuvant setting

The trastuzumab biosimilar HD201 has demonstrated equivalence to the referent drug with respect to total pathologic complete response following neoadjuvant treatment in women with HER2-positive early breast cancer, report the TROIKA investigators.

02-03-2022 | Oncology | News | Article

One in seven screen-detected breast cancers is an overdiagnosis

A modeling study based on data from the US Breast Cancer Surveillance Consortium has found an overdiagnosis rate of 15.4% among women aged 50–74 years undergoing biennial mammographic screening.

01-03-2022 | Oncology | News | Article

EMA recommends extension of abemaciclib indication

Read about this breast cancer decision here